Celgene Strikes Deal Worth Nearly $1 Billion for Blood Cancer Treatment

Celgene has struck another collaborative deal, even as the large pharmaceutical company is in the process of being folded into the operations of its new owner, Bristol-Myers Squibb. This morning, privately-owned drug developer Triphase Accelerator, along with its majority shareholder FACIT, announced it had struck a collaborative deal with Celgene.
Read more...

;